(EMAILWIRE.COM, December 28, 2017 ) The rising prevalence of various cancers, which has led to innovations and technological advancements, drives the development of new immunotherapy drugs that are more effective than the available drugs to treat solid tumors.
Solid tumors are an abnormal mass of tissue that do not contain cysts or liquid areas. These may be malignant (cancerous) or benign (not cancerous). They affect bones, organs, and muscles. Based on the type of the cells, solid tumors can be carcinomas, sarcomas, and lymphomas.

Publisher's analysts forecast the global solid tumors drugs market to grow at a CAGR of 8.6% during the period 2016-2020.

For more information at http://www.reportsweb.com/global-solid-tumors-drugs-market-2016-2020

Covered in this report
The report covers the present scenario and the growth prospects of the global solid tumors drugs market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded drugs, generics, and biosimilars used to treat solid tumors. It also considers the revenues to be generated from the sales of drugs that are anticipated to be launched into the market along with the decline in revenues from the patent expiries of the branded drugs during the forecast period.


The market is divided into the following segments based on geography:
- Americas
- APAC
- EMEA

Publisher's report, Global Solid Tumors Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
- F. Hoffmann-La Roche
- Novartis
- Celgene
- Johnson & Johnson
- Pfizer
- BMS

Request Sample Copy: http://www.reportsweb.com/inquiry&RW0001303202/sample

Other prominent vendors
- AbbVie
- AbGenomics
- ADC Therapeutics
- Advantagene
- Agensys
- Almac Group
- Ambrx
- Argos Therapeutics
- Array BioPharma
- Astellas Pharma
- AstraZeneca
- Bayer
- Biogen
- Biotech Pharmaceutical
- Boehringer Ingelheim
- Boston Biomedical
- Celldex Therapeutics
- Chugai Pharmaceutical
- Cold Genesys
- CTI BioPharma
- Daiichi Sankyo
- DNAtrix
- Ds-Pharma
- Eleison Pharmaceuticals
- Eli Lilly
- Endo Pharmaceuticals
- Formation Biologics
- Fortress Biotech
- Genmab
- GSK
- Immatics Biotechnologies
- Immunogen
- Immunomedics
- Intas Pharmaceuticals
- Kairos Therapeutics
- Kyowa Hakko Kirin
- MedImmune
- Merck
- Mersana Therapeutics
- Morphotek
- Neovii Biotech
- NewLink Genetics
- Northwest Biotherapeutics
- Novartis
- OncoMed Pharmaceuticals
- Oxford Biotherapeutics
- Peregrine Pharmaceuticals
- Polaris Pharmaceuticals
- Sanofi
- Seattle Genetics
- Spectrum Pharmaceuticals
- Stemcentrx
- Synthon Biopharmaceuticals
- TG Therapeutics
- XBiotech

Market driver
- Exposure to risk factors
- For a full, detailed list, view our report

Market challenge
- Patent expiration of top-selling drugs
- For a full, detailed list, view our report

Market trend
- Emergence of targeted and combination therapies
- For a full, detailed list, view our report

Make an enquiry: http://www.reportsweb.com/inquiry&RW0001303202/buying

Contact Information:
ReportsWeb.com
Rajat Sahni
Tel: +1-646-491-9876
Email us


----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results